Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
OncoGenex Pharmaceuticals and Teva Pharmaceutical Industries have just announced the initiation of a new, randomized, controlled, global Phase III trial to evaluate the effectiveness and safety of custirsen ( OGX-011) as first-line therapy for the treatment of metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Uncategorized | Leave a Comment »
The Cancer of the Prostate Risk Assessment or CAPRA scoring system was developed by a group at the University of California at San Francisco (UCSF) as a tool that uses clinical variables to generate a prostate cancer risk-stratification score ranging from 0 to 10.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: CAPRA score, prognosis, risk, startification | 1 Comment »
According to a media release issued earlier today, Medivation and Astellas Pharma have enrolled the first patient into a new Phase III clinical trial of MDV3100.
Filed under: Drugs in development | Tagged: castration-resistant, mCRPC, MDV3100, Phase III, trial | Leave a Comment »
The Centers for Medicare & Medicaid Services (CMS) and the Agency for Healthcare Research and Quality (AHRQ) have now released the final, updated version of a report on the comparative evaluation of various available types of radiation therapy for the treatment of localized prostate cancer. This entire report is available on line.
Filed under: Management, Treatment | Tagged: radiation, Treatment | Comments Off
Elevated levels of free, circulating DNA (fcDNA) have previously been been found in the serum of prostate cancer patients compared with the levels in the serum of patients with benign prostate conditions.
Filed under: Diagnosis, Risk | Tagged: biopsy, circulating, DNA, free, marker | 8 Comments »
An announcement yesterday has made it clear that sunitinib malate (Sutent) is unlikely to ever show significant clinical activity in the management of patients with advanced, castration-resistant prostate cancer (CRPC) after initial chemotherapy.
Filed under: Drugs in development | Tagged: castration-resistant, CRPC, sunitinib | Leave a Comment »
Those who have been assiduously drinking their pomegranate juice will want to be aware of actions taken today by the Federal Trade Commission (the FTC).
Filed under: Living with Prostate Cancer, Management, Prevention | Tagged: pomegranate | 11 Comments »
There have been multiple attempts over the years to try and establish a clear relationship between alcohol consumption and risk for prostate cancer, but despite the multiple attempts there is still no clear picture to work from.
Filed under: Diagnosis, Prevention, Risk | Tagged: alcohol, risk | Leave a Comment »
WARNING: This commentary may not be suitable reading for those who are firmly convinced that annual, mass, population-based screening of all men over (say) 40 or 50 years of age is the right way to manage prostate cancer risk.
Filed under: Diagnosis, Prevention, Risk | Tagged: Management, risk, screening, testing | 20 Comments »
According to a Reuters report based on a recent media release from GTx, the investigational agent GTx-758 is able to induce temporary medical castration in healthy volunteers, making this agent yet another possible candidate for the hormonal management of progressive prostate cancer.
Filed under: Drugs in development | Tagged: advanced, castration, GTx-758 | Leave a Comment »
The ability to predict risk for Gleason score upgrading in patients who have any form of treatment other than radical prostatectomy can be important, because it may help treating physicians and their patients to optimize first-line therapy.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Gleanson scvore, prediction, projection, risk, upgrading | Leave a Comment »
On his Advanced Prostate Cancer blog site, Joel Nowak has just published a series of five brief articles on the opportunities offered by some older agents that are available for use as second-line therapies in the management of patients who have a rising PSA after treatment with standard forms of androgen deprivation therapy (ADT).
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: advanced, castration-resistant, CRPC, estradiol, GM-CSF, ketoconazole, octreotide | 3 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site